Skip to content
Screener

Enovis ENOV Reconstructive — Research and development expense

Other segment segments

Prevention & Recovery
$7.71M—

Similar metrics at other companies

The Cooper Companies, Inc. logo
COOCooperSurgical — Research and development expense
$20.4M+2.5%
The Cooper Companies, Inc. logo
COOCooperVision — Research and development expense
$22.1M-13.7%
TechnipFMC logo
FTISubsea — Research and development expense
$16.7M-8.7%
Becton, Dickinson and Company logo
BDXInterventional — Research and development expense
$72M+14.3%
Becton, Dickinson and Company logo
BDXMedical — Research and development expense
$130.75M+17.0%
Gevo logo
GEVOGevoND — Research and development expense
$0—

Other financials

Income statement

See full
Revenue$582.8M+3.2%
Gross profit$359.2M+7.3%
Operating income$17.4M+204%
Net income-$1.2M+96.8%
EPS (diluted)-$0.02+96.9%

Balance sheet

See full
Cash & equivalents$12.6M-71.5%
Total debt$1.3B-6.4%
Total equity$1.5B-42.7%
Total assets$3.8B-25.0%

Cash flow

See full
Operating cash flow$75.0M+57.1%
CapEx$43.9M-1.1%
Free cash flow$31.1M—

Valuation

See full
Market cap$1.53B-5.5%
Enterprise value$2.83B-4.9%
P/S0.7×-0.1×

Profitability

See full
Gross margin61.1%+3.5pp
Operating margin-45.1%+19.4pp
Net margin-48%+17.7pp
FCF margin-3.1%-1.1pp

Returns & leverage

See full
Return on equity-54.3%+672pp
Debt / equity0.9×+0.3×
Current ratio2×-0.3×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Enovis’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:45 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001420800-26-000035
Line itemThree Months Ended / July 3, 2026Three Months Ended / July 4, 2025Six Months Ended / July 3, 2026Six Months Ended / July 4, 2025
Reconstructive:
Net sales$294,534$273,975$611,667$560,225
Segment cost of sales98,87397,750196,208195,024
Segment research and development23,98021,03147,76640,318
Segment operating expense141,376134,729290,659273,666
Total segment expenses264,229253,510534,633509,008
Add: Depreciation23,68923,95749,41849,354
Adjusted EBITDA (non-GAAP)(1)$53,994$44,422$126,452$100,571

Item 1. Financial Statements

FAQ

What is Enovis's reconstructive — research and development expense?
Enovis (ENOV) reported reconstructive — research and development expense of $23.98M in Q2 2026.
How has Enovis's reconstructive — research and development expense changed year-over-year?
Enovis's reconstructive — research and development expense increased by 14.0% year-over-year, from $21.03M to $23.98M.
What is the long-term trend for Enovis's reconstructive — research and development expense?
Over 3 years (2022 to 2025), Enovis's reconstructive — research and development expense has grown at a 44.9% compound annual growth rate (CAGR), from $27.36M to $83.27M.
What does reconstructive — research and development expense mean?
Expenditures dedicated to the innovation, design, and clinical testing of new reconstructive surgical solutions and technologies. This metric reflects the company's commitment to long-term product pipeline development and maintaining a competitive edge in clinical outcomes.

Ask your AI about Enovis's reconstructive — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude